Live Breaking News & Updates on Professor Sam Lai

Stay updated with breaking news from Professor sam lai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Durham biopharma lands $7M to develop 'muco-trapping' antibody platform


by WRAL TechWire May 26, 2021 .
DURHAM –Inhalon Biopharma is developing a “muco-trapping” antibody platform that could be used to treat acute respiratory infections, including COVID-19, and the Durham-based startup has now been awarded a $7 million contract by the United States Army Medical Research & Development Command (USAMRDC).
The contract will allow the company to conduct a placebo-controlled Phase 1 and Phase 2a study of its technology in COVID-19 outpatients, the company shared in a statement.
The technology, currently designated IN-006, is described by the company as a potent, neutralizing monoclonal antibody that is being investigated as a possible treatment for COVID-19.
The company expects results of the study in 2022. ....

John Whelan , Sam Lai , Inhalon Biopharma , United States Army Medical Research Development Command , Johns Hopkins University , University Of North Carolina At Chapel Hill , United States Army Medical Research , Development Command , Professor Sam Lai , North Carolina , Chapel Hill , Johns Hopkins , Breakout Labs , ஜான் சக்கரம் , சாம் லாய் , ஜான்ஸ் ஹாப்கின்ஸ் பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் வடக்கு கரோலினா இல் தேவாலயம் மலை , ஒன்றுபட்டது மாநிலங்களில் இராணுவம் மருத்துவ ஆராய்ச்சி , வளர்ச்சி கட்டளை , வடக்கு கரோலினா , தேவாலயம் மலை , ஜான்ஸ் ஹாப்கின்ஸ் , பிரேக்அவுட் ஆய்வகங்கள் ,